Literature DB >> 20566929

Adverse events following smallpox vaccination with ACAM2000 in a military population.

Thomas M Beachkofsky1, Scott C Carrizales, Jeffrey J Bidinger, David E Hrncir, Darren E Whittemore, Chad M Hivnor.   

Abstract

BACKGROUND: Generalized vaccinia and benign exanthems are 2 adverse events that have been associated with the smallpox vaccination. Accurate incidence and prevalence rates of each are not readily available, but these events are thought to be uncommon. To our knowledge, this is the first case series to provide clinical as well as pathologic descriptions of multiple papulovesicular eruptions occurring after receiving the second-generation smallpox vaccine, ACAM2000 (Acambis, Canton, Massachusetts), among a vaccinia-naïve military population. In addition, we report the first confirmed case, to our knowledge, of generalized vaccinia following administration of the ACAM2000 vaccine. OBSERVATIONS: All patients received primary smallpox immunization as well as 1 to 3 concurrent or near-concurrent (within the preceding 21 days) immunizations for typhoid, anthrax, hepatitis B, and/or seasonal influenza. One patient presented with a flulike prodrome and diffuse vesiclopustules covering the face, neck, chest, back, and upper and lower extremities. Vaccinia polymerase chain reaction confirmed generalized vaccinia. The remaining 7 patients presented with unusual, painful, and pruritic papulovesicular eruptions occurring on the extensor surfaces of their upper and lower extremities without systemic symptoms. Histologic findings revealed 2 general patterns, including a dermal hypersensitivity reaction with lymphocytic vasculitis and a vesicular spongiotic dermatitis with eosinophils.
CONCLUSIONS: We present the first confirmed case of generalized vaccinia following immunization with the second-generation smallpox vaccine ACAM2000. In addition, we describe 7 cases of benign, acral, papulovesicular eruptions thought to be associated with ACAM2000 administration. Further research is needed to discern the pathogenesis of these benign eruptions as well as their incidence and prevalence and that of generalized vaccinia with ACAM2000.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20566929     DOI: 10.1001/archdermatol.2010.46

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  11 in total

Review 1.  Immune-mediated adverse reactions to vaccines.

Authors:  Cosby A Stone; Christine R F Rukasin; Thomas M Beachkofsky; Elizabeth J Phillips
Journal:  Br J Clin Pharmacol       Date:  2019-11-05       Impact factor: 4.335

Review 2.  Antibodies for biodefense.

Authors:  Jeffrey W Froude; Bradley Stiles; Thibaut Pelat; Philippe Thullier
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

Review 3.  Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors.

Authors:  Stephen R Walsh; Raphael Dolin
Journal:  Expert Rev Vaccines       Date:  2011-08       Impact factor: 5.217

4.  Smallpox vaccine safety is dependent on T cells and not B cells.

Authors:  Shari N Gordon; Valentina Cecchinato; Vibeke Andresen; Jean-Michel Heraud; Anna Hryniewicz; Robyn Washington Parks; David Venzon; Hye-kyung Chung; Tatiana Karpova; James McNally; Peter Silvera; Keith A Reimann; Hajime Matsui; Tomomi Kanehara; Yasuhiko Shinmura; Hiroyuki Yokote; Genoveffa Franchini
Journal:  J Infect Dis       Date:  2011-04-15       Impact factor: 5.226

5.  Glycosylated and nonglycosylated complement control protein of the lister strain of vaccinia virus.

Authors:  Clement A Meseda; Jordan Kuhn; Vajini Atukorale; Joseph Campbell; Jerry P Weir
Journal:  Clin Vaccine Immunol       Date:  2014-07-16

6.  Antibody against extracellular vaccinia virus (EV) protects mice through complement and Fc receptors.

Authors:  Matthew E Cohen; Yuhong Xiao; Roselyn J Eisenberg; Gary H Cohen; Stuart N Isaacs
Journal:  PLoS One       Date:  2011-06-08       Impact factor: 3.240

7.  Impact of ST-246® on ACAM2000™ smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice.

Authors:  Aklile Berhanu; David S King; Stacie Mosier; Robert Jordan; Kevin F Jones; Dennis E Hruby; Douglas W Grosenbach
Journal:  Vaccine       Date:  2010-10-29       Impact factor: 4.169

8.  Characterization of the immune response elicited by the vaccinia virus L3 protein delivered as naked DNA.

Authors:  Maite Ramírez; Saritza Santos; Osmarie Martínez; Ricardo Rodríguez; Eric Miranda; Willy D Ramos-Perez; Miguel Otero
Journal:  Vaccine       Date:  2018-03-07       Impact factor: 3.641

9.  Injection site vaccinology of a recombinant vaccinia-based vector reveals diverse innate immune signatures.

Authors:  Jessamine E Hazlewood; Troy Dumenil; Thuy T Le; Andrii Slonchak; Stephen H Kazakoff; Ann-Marie Patch; Lesley-Ann Gray; Paul M Howley; Liang Liu; John D Hayball; Kexin Yan; Daniel J Rawle; Natalie A Prow; Andreas Suhrbier
Journal:  PLoS Pathog       Date:  2021-01-13       Impact factor: 6.823

Review 10.  Confronting the threat of bioterrorism: realities, challenges, and defensive strategies.

Authors:  Manfred S Green; James LeDuc; Daniel Cohen; David R Franz
Journal:  Lancet Infect Dis       Date:  2018-10-16       Impact factor: 25.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.